Zeng L, Ma G, Chen K, Zhou Q
Front Immunol. 2023; 14:1242336.
PMID: 37869006
PMC: 10587544.
DOI: 10.3389/fimmu.2023.1242336.
Pan M, Zhao H, Jin R, Leung P, Shuai Z
Front Immunol. 2023; 14:1156212.
PMID: 37090741
PMC: 10115969.
DOI: 10.3389/fimmu.2023.1156212.
Dang Q, Watanabe R, Shiomi M, Fukumoto K, Nobashi T, Okano T
Int J Mol Sci. 2023; 24(6).
PMID: 36982715
PMC: 10051463.
DOI: 10.3390/ijms24065643.
Kanannejad Z, Soleimanian S, Ghahramani Z, Sepahi N, Mohkam M, Alyasin S
Front Immunol. 2023; 14:1070779.
PMID: 36865540
PMC: 9972681.
DOI: 10.3389/fimmu.2023.1070779.
Singh J, Minz R, Saikia B, Nada R, Sharma A, Jha S
Clin Exp Med. 2022; 23(5):1801-1813.
PMID: 36219364
DOI: 10.1007/s10238-022-00908-y.
Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy.
Shen P, Deng X, Hu Z, Chen Z, Huang Y, Wang K
Front Med (Lausanne). 2021; 8:762247.
PMID: 34805229
PMC: 8599930.
DOI: 10.3389/fmed.2021.762247.
Successful management of severe bronchial asthma exacerbated by anti-PD-L1 treatment: A report of two cases.
Sumi T, Nagahisa Y, Matsuura K, Sekikawa M, Yamada Y, Nakata H
Respirol Case Rep. 2021; 9(11):e0868.
PMID: 34721879
PMC: 8542805.
DOI: 10.1002/rcr2.868.
Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis.
Miyabe C, Dong Y, Ikeda T, Takahashi K, Miyabe Y, Kawakami T
Sci Rep. 2021; 11(1):20019.
PMID: 34625602
PMC: 8501116.
DOI: 10.1038/s41598-021-99558-5.
Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors.
Barnes Rogers B, Zawislak C, Wong V
J Adv Pract Oncol. 2021; 12(4):392-404.
PMID: 34123476
PMC: 8163252.
DOI: 10.6004/jadpro.2021.12.4.4.
Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report.
Harada M, Naoi H, Yasuda K, Ito Y, Kagoo N, Kubota T
BMC Pulm Med. 2021; 21(1):6.
PMID: 33407304
PMC: 7789237.
DOI: 10.1186/s12890-020-01375-5.
Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
Zhong H, Zhou J, Xu D, Zeng X
Asia Pac J Clin Oncol. 2020; 17(3):178-185.
PMID: 32717098
PMC: 8246553.
DOI: 10.1111/ajco.13346.
Acute Kidney Injury in Oncology Patients.
Wang L, Wang J, Diao Z, Guan Y, Liu W
J Cancer. 2020; 11(16):4700-4708.
PMID: 32626516
PMC: 7330685.
DOI: 10.7150/jca.45382.
Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.
Melissaropoulos K, Klavdianou K, Filippopoulou A, Kalofonou F, Kalofonos H, Daoussis D
Int J Mol Sci. 2020; 21(9).
PMID: 32403289
PMC: 7247001.
DOI: 10.3390/ijms21093389.
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M, Finckh A, Bingham C, Visser K, Leipe J, Schulze-Koops H
Ann Rheum Dis. 2020; 80(1):36-48.
PMID: 32327425
PMC: 7788064.
DOI: 10.1136/annrheumdis-2020-217139.
Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database.
Scanvion Q, Bene J, Gautier S, Grandvuillemin A, Le Beller C, Chenaf C
Oncoimmunology. 2020; 9(1):1722022.
PMID: 32313716
PMC: 7153834.
DOI: 10.1080/2162402X.2020.1722022.
Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
Abdel-Wahab N, Suarez-Almazor M
Rheumatology (Oxford). 2019; 58(Suppl 7):vii40-vii48.
PMID: 31816084
PMC: 6900912.
DOI: 10.1093/rheumatology/kez297.
Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
Kostine M, Truchetet M, Schaeverbeke T
Rheumatology (Oxford). 2019; 58(Suppl 7):vii68-vii74.
PMID: 31816082
PMC: 6900916.
DOI: 10.1093/rheumatology/kez295.
Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
Leipe J, Mariette X
Rheumatology (Oxford). 2019; 58(Suppl 7):vii49-vii58.
PMID: 31816078
PMC: 6900914.
DOI: 10.1093/rheumatology/kez360.
